Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Debt (2022 - 2025)

Historic Total Debt for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $50.9 million.

  • Taysha Gene Therapies' Total Debt rose 1834.03% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 1834.03%. This contributed to the annual value of $43.9 million for FY2024, which is 847.73% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Total Debt stood at $50.9 million, which was up 1834.03% from $41.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Total Debt high stood at $179.1 million for Q3 2023, and its period low was $37.4 million during Q1 2022.
  • Moreover, its 4-year median value for Total Debt was $40.5 million (2023), whereas its average is $49.8 million.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 37410.05% in 2023, then tumbled by 7600.48% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Total Debt (Quarter) stood at $38.0 million in 2022, then grew by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then rose by 15.73% to $50.9 million in 2025.
  • Its Total Debt stands at $50.9 million for Q3 2025, versus $41.1 million for Q2 2025 and $42.5 million for Q1 2025.